Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.
Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. The company also focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions.The DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed and the DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer, including the risk of sentinel lymph node positivity.Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 11, 2018 | Series Unknown | $5.05M | 1 | — | — | Detail |
Aug 13, 2014 | Series Unknown | $11.80M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
MGC Venture Partners | — | Series Unknown |
Longfellow Venture Partners | — | Series Unknown |
Castle Biosciences has acquired 1 organizations. Their most recent acquisition was Cernostics on Oct 19, 2021. They acquired Cernostics for $30M.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Oct 19, 2021
Cernostics
|
Biotechnology | acquisition | $ 30M | Detail |